(Q50803241)

English

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (

scientific article published in June 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen ( (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Nagalingeswaran Kumarasamy

3

object named as

N Kumarasamy

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

author name string

SECOND-LINE Study Group

1

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

M A Boyd

2

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

C L Moore

4

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

C Nwizu

5

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

M H Losso

6

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

L Mohapi

7

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

A Martin

8

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

S Kerr

9

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

A H Sohn

10

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

H Teppler

11

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

O Van de Steen

12

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

J-M Molina

13

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

S Emery

14

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

D A Cooper

15

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

language of work or name

0 references

publication date

1 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

381

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

9883

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

2091-2099

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

Antiretroviral roll-out: the problem of second-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961164-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)61164-2

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23769235

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50803241&oldid=2212216060"